Literature DB >> 1744452

Growth factors and pancreatic cancer.

M Korc1.   

Abstract

Cultured human pancreatic cancer cells produce a number of growth factors, including transforming growth factor-alpha (TGF-alpha). These cells also overexpress the epidermal growth factor (EGF) receptor and exhibit a parallel increase in EGF receptor mRNA levels. TGF-alpha, which binds to the EGF receptor, is more potent than EGF in enhancing the anchorage-independent growth of several pancreatic cancer cell lines, including T3M4 cells. In contrast, EGF is more efficient than TGF-alpha with respect to EGF receptor downregulation and tyrosine phosphorylation in T3M4 cells. Further, T3M4 cells recycle EGF, but markedly degrade TGF-alpha. It is suggested that the production of multiple growth factors, the overexpression of the EGF receptor, the recycling of EGF, and the attenuated ability of TGF-alpha to downregulate the EGF receptor combine to enhance the growth advantage of human pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744452     DOI: 10.1007/bf02925583

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  34 in total

1.  Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha.

Authors:  M Korc; J E Finman
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

2.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle.

Authors:  J J Smith; R Derynck; M Korc
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing.

Authors:  A M Honegger; T J Dull; S Felder; E Van Obberghen; F Bellot; D Szapary; A Schmidt; A Ullrich; J Schlessinger
Journal:  Cell       Date:  1987-10-23       Impact factor: 41.582

4.  Detection of human lung epithelial cell growth factors produced by a lung carcinoma cell line: use in culture of primary solid lung tumors.

Authors:  J M Siegfried
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

5.  Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer.

Authors:  M Korc; P Meltzer; J Trent
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

6.  Genetic analysis of hyperproduction of epidermal growth factor receptors in human epidermoid carcinoma A431 cells.

Authors:  N Shimizu; I Kondo; S Gamou; M A Behzadian; Y Shimizu
Journal:  Somat Cell Mol Genet       Date:  1984-01

7.  Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-alpha and epidermal growth factor.

Authors:  Y Barrandon; H Green
Journal:  Cell       Date:  1987-09-25       Impact factor: 41.582

8.  Divergent effects of epidermal growth factor and transforming growth factors on a human endometrial carcinoma cell line.

Authors:  M Korc; C A Haussler; N S Trookman
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

9.  Human recombinant transforming growth factor alpha stimulates bone resorption and inhibits formation in vitro.

Authors:  K J Ibbotson; J Harrod; M Gowen; S D'Souza; D D Smith; M E Winkler; R Derynck; G R Mundy
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

10.  Recycling of epidermal growth factor in a human pancreatic carcinoma cell line.

Authors:  M Korc; B E Magun
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

View more
  7 in total

Review 1.  Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.

Authors:  Andrew D Rhim; Ben Z Stanger
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 2.  Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation.

Authors:  Stacey J Coleman; Jennifer Watt; Prabhu Arumugam; Leonardo Solaini; Elisabeta Carapuca; Mohammed Ghallab; Richard P Grose; Hemant M Kocher
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis.

Authors:  D Birk; F Gansauge; S Gansauge; A Formentini; A Lucht; H G Beger
Journal:  Int J Pancreatol       Date:  1999-04

Review 4.  Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer.

Authors:  J D Liao; N V Adsay; F Khannani; D Grignon; A Thakur; F H Sarkar
Journal:  Histol Histopathol       Date:  2007-06       Impact factor: 2.303

5.  Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin).

Authors:  P Büchler; H A Reber; M C Büchler; M A Roth; M W Büchler; H Friess; W H Isacoff; O J Hines
Journal:  J Gastrointest Surg       Date:  2001 Mar-Apr       Impact factor: 3.452

6.  Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions.

Authors:  L O Murphy; M W Cluck; S Lovas; F Otvös; R F Murphy; A V Schally; J Permert; J Larsson; J A Knezetic; T E Adrian
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

7.  Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins.

Authors:  M Löhr; B Trautmann; M Göttler; S Peters; I Zauner; B Maillet; G Klöppel
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.